On Thursday, Shares of Horizon Pharma plc (NASDAQ:HZNP), surged 4.98% to $30.97, hitting its highest level, after a specialty biopharmaceutical company declared the pricing of its underwritten public offering of 15,350,000 of its ordinary shares at $28.25 per share.
The Dublin, Ireland-based company anticipates to proceeds from the offering, which is predictable to close April 21, to be about $413.1 million. Underwriters will have an additional 30 days to purchase up to 2,302,500 ordinary shares.
Citigroup (C), Jefferies (JEF), Cowen and Company (COWN), and Morgan Stanley (MS) are acting as joint book-running managers for this offering.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), gained 4.79% to $0.7650, during the last trading session on Thursday.
Rexahn Pharmaceuticals, declared that it will have two poster presentations at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in Philadelphia, Pennsylvania, on April 18-22, 2015 at the Pennsylvania Convention Center.
The first poster (abstract #2622) entitled, “Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker” on Monday, April 20, 2015, during the “Novel Mechanisms of Drug Pharmacology and Toxicity” poster session from 1:00 pm — 5:00 pm in Poster Section 30.
The second poster (abstract #3577) entitled, “Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)” for RX-5902 will be presented on Tuesday, April 21, 2015, during the “Molecular Targets” poster session from 8:00 am — 12:00 pm in Poster Section 30.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), in addition to a pipeline of preclinical compounds to treat multiple types of cancer.
At the end of Thursday’s trade, Shares of TrueCar, Inc. (NASDAQ:TRUE), gained 4.57% to $16.47.
TrueCar, has raised its commitment to attracting top technology talent to support its expanding business operations by opening a new 8,300-square-foot office in San Francisco’s SoMa district.
TrueCar now occupies the 24th floor of the art deco 140 New Montgomery tower, near the Yerba Buena Gardens and San Francisco Museum of Modern Art. The new space will house TrueCar’s expanding engineering and data analytics teams.
Developers in San Francisco will focus on advanced R&D, developing and launching new consumer-facing and data products. The work there will complement efforts at TrueCar’s Santa Monica headquarters.
The office was designed by Shubin + Donaldson Architects, Inc., a firm with offices in Santa Barbara and Los Angeles. “The design intent is modeled on TrueCar’s motto of transparency,” said designer Chris Pilikyan. “Glass walls run floor to ceiling; stand in one corner and you can see all the way through.”
TrueCar, Inc. operates as an Internet-based information, technology, and communication services company. The company operates its platform on the TrueCar Website and TrueCar mobile applications.
Finally, Full Circle Capital Corporation (NASDAQ:FULL), ended its Thursday’s trading session with 4.51% gain, and closed at $3.71.
On March 31, Full Circle Capital Corporation, declared the successful completion of its non-transferable rights offering, which expired on March 30, 2015 as planned.
The Company received subscriptions for about 94% of the shares offered, 17% of which represents commitments by administration and Full Circle Advisors.
In addition, an institutional investor has committed to purchase about 214,000 shares in open market transactions over a seven-day period following the expiration date of the rights offering. Such investor has agreed to attain the remainder of its committed shares in a private placement at $3.50 per share directly from the Company to the extent such shares are not purchased in open market transactions during such seven-day period.
The rights offering and additional commitments will result in the issuance of no more than 11,420,207 additional shares of the Company’s common stock. The foregoing results are based upon the subscriptions for shares received, and remain subject to receipt of final payment for such shares in accordance with the terms and conditions of the rights offering.
Estimated gross proceeds from the rights offering, before payment of dealer-manager fees and other offering expenses, are predictable to be about $39 million. The net proceeds will be used by the Company for the origination of new investments in accordance with its investment objective, and for working capital and other general corporate purposes. The subscription price for the rights was $3.50 per share.
Ladenburg Thalmann & Co. Inc. acted as the dealer manager for the rights offering.
Full Circle Capital Corporation is a business development company specializing in debt and equity securities of smaller and lower middle-market companies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
